nContact develops arrhythmia disease-management programs and the Convergent Procedure, a multidisciplinary epicardial–endocardial approach for persistent atrial fibrillation. Its lead technology is the EPi-Sense Coagulation System with VisiTrax, which has CE Mark approval in Europe and is indicated for endoscopic coagulation of cardiac tissue in the U.S. The company is conducting the randomized CONVERGE IDE clinical trial, the first head-to-head study comparing the Convergent Procedure to traditional catheter ablation in persistent AF. nContact plans to use new financing to support the CONVERGE trial, expand field support teams, and advance next-generation product development. Management has emphasized partnerships with hospitals adopting Disease Management Programs to address readmissions and provide continuum of care for chronic disease patients. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina. nContact Surgical develops a guided epicardial ablation device that integrates suction, perfusion, and RF energy to create visible, continuous, non-conductive bi-atrial lesions applied endoscopically on a beating heart. The technology is FDA-cleared in the U.S. for endoscopic cardiac coagulation and is being further evaluated in IDE clinical trials for the treatment of atrial fibrillation in both open and closed chest procedures. The company says its device has enabled the Convergent Procedure, which brings together a cardiac surgeon and an electrophysiologist into a comprehensive, potentially closed-chest treatment option for difficult AF patients. nContact intends to use new capital to support ongoing clinical trials, further product development, and to hire for new positions. The company also recently received a $244,479 federal Qualifying Therapeutic Discovery Project grant.

Total raised

$36M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2014